Company News

T&L Biotechnology proudly introduces comprehensive exosome services—designed to support every stage of your journey, from extraction and purification to GMP-grade lyophilization.

🌟 What we offer:
✔ Cutting-edge freeze-drying technology for stable, ready-to-use exosome powders.
✔ High-purity solutions with rigorous quality control (>95% purity).
✔ Full-spectrum support tailored to aesthetics, regenerative medicine, and therapeutic innovation.

Discover how our end-to-end solutions empower researchers and businesses to unlock the immense potential of exosomes.

💡 Ready to elevate your project? Explore more here:

When a client's Nk Cell culture faced a critical survival crisis—starting with only 47% viability and poor expansion efficiency—T&L Biotechnology's expert team intervened with precision and expertise. In just 17 days, we achieved an incredible 500-fold expansion and a 90.8% positive rate. Here's how we did it.

✅ ​​Core Advantages​​
✓ 5x Higher Bioactivity (Validated with Mo7e cells)
✓ Ultra-High Purity >90% (SDS-PAGE Certified)
✓ Low Endotoxin <1.0 EU/μg

🔬 ​​Applications​​
▸ Cord Blood HSC Expansion
▸ In Vitro Drug Screening Platforms
▸ Bone Marrow Failure Research

📊 ​​Data Highlights​​
⭐ 3-fold Increase in CFU with SCF/IL-3 Synergy
⭐ Maintains HSC Quiescence for 72h+

🚀 We're off to New Orleans—see you at T&L Biotechnology's booth!

T cells play a crucial role in our immune system, and T cell therapies are breaking ground in treating challenging diseases like cancer and autoimmune disorders. A key step in T Cell Therapy,T cell activation, directly impacts therapeutic outcomes. That’s why we're excited to introduce our ActCel T Cell Activation Reagent (Cat. No. TL-6001-1000) — designed for gentle, efficient activation to support high cell viability and expansion.

Key Features
✔️ Safe and Effective: Gentle activation for robust cell expansion
✔️ Easy to Use: Ready-to-use format
✔️ Cost-Effective: Reliable performance with competitive pricing

Autoimmune diseases are a global health challenge, affecting nearly 10% of the population. But what if I told you there's a potential breakthrough in treating these conditions?

We're excited to share our latest webinar, " Understanding Autoimmune CAR-T Therapy," featuring Dr. Allan Zhang. In this insightful session, Dr. Zhang explores the cutting-edge of CAR-T technology and its application in autoimmune diseases, offering hope for drug-free remission.

We are delighted to announce that T&L Biotechnology will be participating in the 31st Annual ESGCT Congress, a premier event in gene and cell therapy.

Don't miss this chance to be part of a transformative event. For more information or to set up a meeting, please contact us directly. We are excited to welcome you to our booth and discuss how T&L Biotechnology can be a valuable partner in your scientific journey.

See you in Rome!

Cell therapy has developed rapidly in recent years in pharmaceutical research and development, and is a new drug development model that has shown great potential in the treatment of diseases such as cancer, infectious diseases, and autoimmune diseases.

Recently, Beijing T&L Biotechnology Ltd. (referred to as "T&L") successfully obtained the US FDA DMF registration for its CGT core raw material CD28 monoclonal antibody, with DMF registration number 038820.

Recently, Beijing T&L Biotechnology Ltd. (hereinafter referred to as "T&L") received a confirmation letter from the US Food and Drug Administration (hereinafter referred to as "FDA"), stating that the company's key raw materials for cell therapy drugs, CD3 monoclonal antibody, and T cell sorting activation magnetic beads, have officially completed the DMF type II filing with the US FDA.